(COMTEX) B: Chromatics to Commence Mass Manufacturing of LED Color Me
B: Chromatics to Commence Mass Manufacturing of LED Color Measurement
Instruments
NEW YORK, Jan 5, 2001 /PRNewswire via COMTEX/ -- Chromatics Color Sciences
International, Inc. (Nasdaq: CCSI) announced today that it has successfully
completed a prototype of an LED (light emitting diode) color measurement
instrument for mass manufacturing. The instrument has been under development in
conjunction with the Company's proprietary color science technology.
The LED instrument incorporates inexpensive light emitting diode technology in a
miniaturized design to measure color precisely but at a sharply reduced cost.
The higher cost of existing color measurement instruments has limited their use
in the marketplace, whereas the new Chromatics LED instruments will be
producible in quantity at a cost of less than $500 to end users.
Brian Fitzpatrick, President & Acting Chief Executive Officer, commented, "This
is a significant achievement for the Company. With the completion of the
low-cost LED prototype, Chromatics is positioned competitively to commercialize
its color science technology across a number of targeted industries. The device
has immediate applications in the beauty industry and next generations are
scheduled for the dental and medical markets. Our LED products and technologies
will signal the start of a new era in color measurement systems in which CCSI
expects to define and capture the standard."
Chromatics Color Sciences is in the business of color science and has developed
technologies and intellectual properties in this field. The Company has received
clearance from the Food and Drug Administration (FDA) for the commercial use of
its medical device for the non-invasive monitoring of hyperbilirubinemia in
newborn infants by healthcare professionals in hospitals, clinics, pediatrician
offices and the home environment. The Company believes its technologies and
intellectual properties may also have medical applications in the detection and
monitoring of other chromogenic diseases which the Company defines as those
diagnosed or monitored by the coloration of the human skin, tissue or fluid
being affected. Medical applications, in addition to the non-invasive monitoring
of hyperbilirubinemia in newborns, will require additional clinical trials and
FDA clearances for commercial use. The LED instrument for use in monitoring
hyperbilirubinemia also will require further FDA clearances for commercial use.
The Company's technologies and intellectual properties also have other
applications including the scientific color measurement and classification of
human skin and certain color-sensitive consumer products, and in determining the
color compatibility of such skin and product color classification for use in a
variety of industries including the cosmetic, beauty-aid and fashion industries.
Certain of the matters discussed in this announcement contain forward- looking
statements that involve material risks to and uncertainties in the Company's
business that may cause actual results to differ materially from those
anticipated by the statements made herein. Such risks and uncertainties include,
among other things, the availability of any needed financing, the Company's
ability to implement its long range business plan for various applications for
its technologies, the Company's ability to enter into agreements with additional
marketing and distribution partners, the impact of competition, the obtaining
and maintaining of any necessary regulatory clearances applicable to
applications of the Company's technology, management of growth and other risks
and uncertainties that may be detailed from time to time in the Company's
reports filed with the Securities and Exchange Commission, including those set
forth in its annual report on Form 10-K for the year ended December 31, 1999 and
on Form 10-Q for the quarter ended September 30, 2000.
SOURCE Chromatics Color Sciences International, Inc.
CONTACT: Investor Relations of Chromatics Color Sciences International
Inc., 212-717-6544; or Rick Matthews of Rubenstein Associates
Inc., Public
Relations, 212-843-8007, for Chromatics Color Sciences Intern
tional, Inc.
(CCSI)
prnewswire.com
(C) 2001 PR Newswire. All rights reserved.
-0-
KEYWORD: New York
INDUSTRY KEYWORD: HEA
CPR
SUBJECT CODE: PDT
*** end of story *** |
